Uso do estimulante de colônia de granulócitos nas neutropenias em cães e gatos

Lucidi, Cynthia de A.; Takahira, Regina Kiomi

doi:10.1590/s0103-84782007000300054

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The three dogs that presented severe neutrophilic leukopenia (25% of cases) underwent treatment with rhG-CSF. Its use is one of the recommended therapeutic options in cases of severe neutropenia after chemotherapy treatment (LUCIDI & TAKAHIRA, 2007). The use in the cases observed in the study was important to avoid serious conditions related to infections and sepsis.…”

Section: Costa Et Almentioning

confidence: 98%

Lomustine for treatment of canine transmissible venereal tumor

et al. 2023

View full text Add to dashboard Cite

Canine transmissible venereal tumor (TVTC) is a highly casuistic transmissible neoplasm in Brazil. Chemotherapy with vincristine sulfate is considered the treatment of choice, but the need for weekly applications and hematological monitoring, in addition to costs, are obstacles to owners’ adhesion to the treatment. Lomustine is an alkylating class antineoplastic agent, and because it is administered orally, it is a more practical and less costly treatment option for the owners of animals with neoplasms sensitive to the drug. This study evaluated the therapeutic efficacy of lomustine in dogs affected by TVTC. Twelve dogs with cytopathological diagnosis of natural genital TVTC were selected. The dogs were submitted to the experimental protocol with lomustine administration at doses of 70 to 85 mg/m2 orally every 21 days, totaling a maximum of two administration cycles. The animals were reevaluated every 7 days until a maximum of +49 days after the first dose of lomustine, to monitor the regression of neoplastic lesions through measurements. Among the 12 dogs submitted to the lomustine protocol, 8/12 achieved complete remission of the neoplasm and were considered cured (66.6%), 1/12 had partial response to treatment (8.33%) and 3/12 had stable disease (25%). Important adverse effects such as severe neutrophilic leukopenia were detected in 3/12 dogs (25%). The clinical study indicated that lomustine may be a treatment option for TVTC.

show abstract